Send your comments and tips to email@example.com
Beth Israel Deaconess Medical Ctr.
Boston Medical Center
Brigham and Women's Hospital
Cambridge Health Alliance
Caritas St. Elizabeth's Medical Ctr.
Children's Hospital Boston
Dana-Farber Cancer Institute
Joslin Diabetes Center
Mass. General Hospital
Mass. Health Law
New England Baptist Hospital
Short White Coat
Tufts-New England Medical Center
UMass Memorial Medical Center
University of Massachusetts
VA Medical Centers
A Healthy Blog
Running A Hospital
Nature Network Boston
SciBos - Corie Lok's blog
Nurse at small
Dr. Gwenn Is In
Healthy Children blog
Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Boston Globe Health and Science staff:
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
Short White Coat blogger Ishani Ganguli
Short White Coat blogger Jennifer Srygley
Monday, June 11, 2007
Today's Globe: alternative therapies, spiritual needs, culture change, Alzheimer's test, biologics standards
Most cancer patients try herbs, vitamins, or other untested treatments in search of relief, or even a cure. Now, scientists are figuring out which ones might really work.
At Massachusetts General Hospital, the Clinical Pastoral Education program trains people who are already healthcare providers to attend better to their patients' spiritual needs, including Alyssa Rosen (left), a fourth year Harvard Medical School student who just graduated from the program.
Brock Reeve (left) was hired last year as the Harvard Stem Cell Institute's executive director to broker agreements and transform the way researchers at Harvard and affiliate institutions pursue stem cell science to treat and cure disease. So far, scientists and others give Reeve glowing reviews.
New tests involving blood and brain scans can detect symptoms of Alzheimer's disease, and brief appraisals of real-life functioning can predict who is likely to develop it, researchers said yesterday.
The rush by some in Congress to create a new market for generic drug makers in the field of biologics, (biotech drugs produced from living cell cultures rather than synthesized chemically) would actually sacrifice patient safety over the long term, Una S. Ryan, president and chief executive officer of AVANT Immunotherapeutics Inc., writes on the op-ed page.